Dupilumab had a fivefold improvement in sustained disease remission in bullous pemphigoid compared with placebo, along with a significant reduction in oral corticosteroid use.
A Prescription Drug User Fee Act target date of June 20, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback